1 BTC
=
- USD
NRX Pharmaceuticals, Inc. Common Stock
As of May 30, 2026 at 24:05 UTC
Chart
About NRX Pharmaceuticals, Inc. Common Stock
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company is developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.
Market Statistics
Trading Metrics
How to Buy NRXP
Create Your Account
Sign up, deposit BTC, and transfer it to your Unified Trading Account. It only takes a moment.
Start Your Trade
From Terminal, click Trade Now on the asset you want to buy. You'll be purchasing its tokenized asset.
Buy NRXP
Enter the amount and confirm your purchase. That's it! You'll see the impact of the trade in your Unified Trading Account.
New to Tokenized Assets? Learn more in our Help Center.
Latest News
5 articlesWith stabilizing interest rates and increased FDA activity, three biotech companies stand out: Schrödinger combines AI-driven drug discovery with established software revenue ($256M in 2025); Sarepta generates nearly $2B in annual product revenue from gene therapy despite ongoing safety concerns around Elevidys; and NRX Pharmaceuticals, a speculative small-cap, has regulatory momentum with FDA decisions expected this summer for depression and suicidality treatments.
NRx Pharmaceuticals reported Q1 2026 financial results showing a net loss of $1.4 million, improved from $5.5 million in Q1 2025. The company advanced its preservative-free ketamine ANDA toward FDA approval expected in Q3 2026, initiated commercial manufacturing, and received FDA clearance for a Phase 2b/3 trial of NRX-101 combined with robotic-assisted TMS. The company also won a bid to acquire Geneuro's HERV-targeting asset portfolio and expanded its HOPE Therapeutics clinic network to five locations.
NRx Pharmaceuticals announced it will release its first quarter 2026 financial results on May 18, 2026, followed by a conference call. The clinical-stage biopharmaceutical company is developing NMDA platform-based therapeutics for CNS disorders, with NRX-100 (preservative-free intravenous ketamine) and NRX-101 (oral D-cycloserine/lurasidone) in development. NRX-100 has received Fast Track Designation and NRX-101 has received Breakthrough Therapy Designation for treating suicidal bipolar depression.
NRx Pharmaceuticals announced the appointment of Glenn Tyson as its first Chief Commercial Officer. Tyson brings 25 years of pharmaceutical industry experience and clinical background in mental health treatment. The appointment comes as NRx anticipates FDA approval of its preservative-free ketamine ANDA and prepares to submit a New Drug Application to expand ketamine labeling for depression and suicidality treatment.
NRx Pharmaceuticals received FDA preliminary alignment on labeling for its preservative-free ketamine generic drug application, with only minor formatting changes required. The company expects final approval under GDUFA in Summer 2026. The product addresses ketamine supply shortages and is manufactured in the US, aligning with FDA's focus on re-shoring critical drug supply elements.